Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#338 of 388

Emily Bodnar

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2022No new ratings since Jul 2025

Analyst rating accuracy & track record

Emily Bodnar is an equity research analyst at HC Wainwright & Co.. Quantellect has scored 149 of their stock calls across 23 companies. Their picks beat their sector 22% of the time over the next 12 months, and their price targets were reached 11% of the time within a year.

Win % vs sector
22%
PT Hit % (12mo)
11%
Avg sector-excess
−20.6%
Scored calls
149
Tickers
23
Tier
Established

Track record

Quantellect has scored 149 of Emily Bodnar's stock calls across 23 companies, dating back to 2022. Their rated stocks beat their own sector 22% of the time over the next 12 months. On a typical call, a Bodnar pick returned −20.6% more than its sector over the following year.

Of the scored calls, 149 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
NXTCNextCure  Inc
Buy$3.00Jul 2025−81.4%Miss
FEMYFemasys Inc
Buy$12.00Jun 2025+248.8%Miss
ARTVArtiva Biotherapeutics, Inc. Common Stock
Buy$12.00Jun 2025+275.6%Hit
FEMYFemasys Inc
Buy$12.00Jun 2025+402.1%Miss
AGENAgenus Inc
Buy$25.00Jun 2025−50.4%Miss
SABSSAB Biotherapeutics Inc
Buy$10.00May 2025+87.3%Miss
FEMYFemasys Inc
Buy$12.00May 2025−69.7%Miss
SANASana Biotechnology Inc
Buy$11.00Apr 2025+79.6%Miss
RNAZTranscode Therapeutics Inc
Buy$10.00Apr 2025+3.9%Miss
VTVTvTv Therapeutics Inc
Buy$36.00Apr 2025+93.5%Hit
CNTBConnect Biopharma Holdings Ltd
Buy$8.00Apr 2025+327.1%Miss
GNLXGenelux Corporation Common Stock
Buy$30.00Mar 2025−11.0%Miss
CNTBConnect Biopharma Holdings Ltd
Buy$8.00Mar 2025+353.8%Miss
FEMYFemasys Inc
Buy$15.00Mar 2025−70.2%Miss
ACRVAcrivon Therapeutics, Inc. Common Stock
Buy$19.00Mar 2025−36.7%Miss
NKTXNkarta Inc
Buy$18.00Mar 2025+2.1%Miss
ATOSAtossa Genetics Inc
Buy$7.00Mar 2025−57.4%Miss
ACRVAcrivon Therapeutics, Inc. Common Stock
Buy$19.00Mar 2025−46.0%Miss
GNLXGenelux Corporation Common Stock
Buy$30.00Mar 2025−20.0%Miss
CNTXContext Therapeutics Inc
Buy$5.00Mar 2025+295.2%Miss
FEMYFemasys Inc
Buy$15.00Mar 2025−65.3%Miss
SANASana Biotechnology Inc
Buy$11.00Mar 2025+31.8%Miss
INKTMink Therapeutics Inc
Buy$35.00Mar 2025+17.5%Hit
FEMYFemasys Inc
Buy$12.00Mar 2025−63.7%Miss
NXTCNextCure  Inc
Buy$3.00Mar 2025+73.9%Miss
FEMYFemasys Inc
Buy$12.00Mar 2025−69.0%Miss
ATOSAtossa Genetics Inc
Buy$7.00Mar 2025−57.1%Miss
NXTCNextCure  Inc
Buy$3.00Mar 2025+35.5%Miss
FEMYFemasys Inc
Buy$12.00Feb 2025−73.7%Miss
RCUSArcus Biosciences Inc
Buy$24.00Feb 2025+89.0%Hit
INKTMink Therapeutics Inc
Buy$35.00Feb 2025+14.8%Hit
AGIOAgios Pharm
Buy$58.00Feb 2025−21.5%Miss
FEMYFemasys Inc
Buy$12.00Feb 2025−70.8%Miss
TNYATenaya Therapeutics Inc
Buy$18.00Feb 2025−17.9%Miss
ATOSAtossa Genetics Inc
Buy$7.00Jan 2025−40.1%Miss
NVCRNovocure Ltd
Buy$38.00Jan 2025−62.0%Miss
SANASana Biotechnology Inc
Buy$11.00Jan 2025+8.3%Miss
ATOSAtossa Genetics Inc
Buy$7.00Dec 2024−47.3%Miss
ATOSAtossa Genetics Inc
BuyDec 2024−37.6%
ACLXArcellx Inc
Buy$115.00Dec 2024−31.8%Miss
GERNGeron Corporation
Buy$9.00Dec 2024−76.8%Miss
NVCRNovocure Ltd
Buy$38.00Dec 2024−67.2%Miss
FEMYFemasys Inc
Buy$12.00Dec 2024−27.5%Miss
NVCRNovocure Ltd
Buy$38.00Dec 2024−71.2%Miss
SANASana Biotechnology Inc
Buy$8.00Nov 2024+45.8%Miss
FEMYFemasys Inc
Buy$12.00Nov 2024−18.7%Miss
NVCRNovocure Ltd
Buy$30.00Nov 2024−41.8%Hit
GNLXGenelux Corporation Common Stock
Buy$30.00Nov 2024+90.8%Miss
INKTMink Therapeutics Inc
Buy$9.00Nov 2024+63.9%Miss
PPBTPurple Biotech
Buy$33.00Nov 2024−80.5%Miss
Go to

Emily Bodnar: analyst track record FAQ

Is Emily Bodnar a good stock analyst?

Yes, by track record. Emily Bodnar ranks number 338 of 388 of the analysts Quantellect scores, with a Q Score of 0 out of 100. Past results do not guarantee future ones.

What is Emily Bodnar's win rate?

Emily Bodnar's win rate is 22%. Across 149 scored calls, their rated stocks beat their sector 22% of the time over the next 12 months. On a typical call they returned −20.6% more than the sector.

What stocks and sectors does Emily Bodnar cover?

Emily Bodnar covers 23 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Emily Bodnar's price targets accurate?

Emily Bodnar's price targets are reached within 12 months 11% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Emily Bodnar's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Emily Bodnar rank among Wall Street analysts?

Emily Bodnar ranks number 338 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.